A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy

Luminari S, Pinto A, Puccini B, D’Arpino A, Omodeo Salè E, Bellone M, Pradelli L, Sabinot A

ClinicoEconomics and Outcomes Research 2025, 17:335-348

Published Date: 16 April 2025